Abstract:Two clusters (C1 and C2) were determined, for which C1 with a poor prognosis had higher immune infiltration. A four‐gene signature was developed and successfully validated. Background The cell endocrine pathway is a critical physiological process composed of the endoplasmic reticulum, Golgi apparatus and associated vesicles. Loss of enzymes or proteins can cause dysfunction of endoplasmic reticulum and Golgi apparatus and affect secretion pathways leading to a variety of human diseases, including cancer. Methods The single‐cell RNA sequencing and single nucleotide variant principal component analysis data of ovarian cancer were retrieved from The Cancer Genome Atlas and Gene Expression Omnibus (GEO) datasets. Eighty‐four genes from SECRETORY_PATHWAYs were obtained from the gene set enrichment analysis (GSEA) website. Univariate cox regression analyses and ConsensusClusterPlus were used to identify prognostic genes and molecular subtypes, which were validated using the tumor immune dysfunction and exclusion (i.e. TIDE) analysis and gene mutation analysis. A prognosis model was established by randomForestSRC. Abundant infiltrated immune cells and pathway enrichment analyses were carried out, respectively, through ssGSEA, ESTIMATE, MCP‐counter and GSEA. The drug sensitive analysis was performed using pRRophetic package. Immunotherapy datasets and pan‐carcinoma analysis were used to examine the performance of prognostic model. Results Eighteen prognostic genes from SECRETORY_PATHWAYs were found in both TCGA and GEO datasets. Next, two clusters (C1 and C2) were determined, for which C1 with a poor prognosis had higher immune infiltration. Tumor‐related pathways, such as PATHWAYS_IN_CANCER and B_CELL_RECEPTOR_SIGNALING_PATHWAY, were enriched in C1. Moreover, C2 was suitable for immunotherapy. A four‐gene (DNAJA1, NDRG3, LUZP1 and ZCCHC24) signature was developed and successfully validated. RiskScore of higher levels were significantly associated with worse prognoses. An enhanced immune infiltration, increased pathways score and inappropriate immunotherapy were observed in the high RiskScore group. The high‐ and low‐RiskScore groups had different drug sensitivities. Immunotherapy datasets and pan‐carcinoma analysis indicated that the low RiskScore group may benefit from immunotherapy. Conclusions Based on the perspective of the secretory signaling pathway, a robust prognostic signature with great performances was determined, which may provide clues for clinical precision treatment of ovarian cancer.

Beyond the estrogen receptor: In search of predictive biomarkers for low‐grade serous ovarian cancer

Predictive markers of endocrine response in breast cancer

Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues

Updates on breast biomarkers

Improving response to progestin treatment of low-grade endometrial cancer

Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer

Estrogen Receptor-Related Genes As An Important Panel Of Predictors For Breast Cancer Response To Neoadjuvant Chemotherapy

Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers

Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry

A Clinically Applicable Molecular Classification for High-Grade Serous Ovarian Cancer Based on Hormone Receptor Expression.

The Prognostic Significance Of Estrogen And Progesterone Receptors In Grade I And Ii Endometrioid Endometrial Adenocarcinoma: Hormone Receptors In Risk Stratification

The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers

Comprehensive profiling of endocrine metabolism identifies a novel signature with robust predictive value in ovarian cancer

Estrogen Receptor- And Progesterone Receptor-Positive Thresholds in Predicting the Recurrence of Early Low-Risk Endometrial Cancer

Past, Present, and Future of Serum Tumor Markers in Management of Ovarian Cancer: A Guide for the Radiologist

Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications

Biomarkers for the clinical management of breast cancer: International perspective

Value of Pre-Treatment Biomarkers in Prediction of Response to Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Postmenopausal Breast Cancer.

Characterization of Ovarian Clear Cell Carcinoma Using Target Drug-Based Molecular Biomarkers: Implications for Personalized Cancer Therapy

Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer